Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,413 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Intimation of Schedule of Analyst/Institutional Investor Meeting
Regulatory Filings Classification · 85% confidence The document is an intimation under Regulation 30 of SEBI LODR, notifying the stock exchanges of the schedule for analyst/institutional investor meetings. It contains no financial data, no formal report, and is purely a regulatory compliance announcement. This fits the general “Regulatory Filings” category (RNS) rather than any specific financial report, presentation, or other event category.
2026-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is an intimation under SEBI Listing Obligations Regulations notifying stock exchanges of the schedule of upcoming analyst/institutional investor meetings. It does not contain financial statements, presentations, or substantive report content; rather, it is a regulatory disclosure notice. This fits the “Regulatory Filings” category (RNS) for general compliance announcements.
2026-05-27 English
Filing of Application for reclassification with stock exchanges
Regulatory Filings Classification · 88% confidence The document is a stock exchange intimation under SEBI Listing Obligations (Regulations 30 and 31A) regarding the company’s application for reclassification of its shareholding category from ‘Promoter Group’ to ‘Public’. It does not contain financial statements, voting results, management changes, or any detailed report—it is a routine regulatory announcement under listing rules. This aligns with Regulatory Filings (RNS), which serves as the fallback category for compliance disclosures to stock exchanges.
2026-05-26 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an SEBI Listing Regulations intimation regarding the filing of an application for reclassification of shareholding category (from Promoter Group to Public). It is an announcement/disclosure under listing obligations (Regulation 30/31A) rather than a substantive financial report, management discussion, or dividend notice. It does not fit specialized categories like MRQ (threshold crossing) or SHA (capital change). It is therefore best classified as a general regulatory announcement (Regulatory Filings).
2026-05-26 English
Press Release
Regulatory Filings Classification · 85% confidence The document is an “Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)” to the Indian stock exchanges enclosing a press release about clinical trial data. It does not contain financial results or an investor presentation, nor is it the text of an earnings release or formal financial report. It is a general regulatory announcement/press release to exchanges, which falls under the Regulatory Filings category.
2026-05-26 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a press release served as an intimation under SEBI Regulation 30 to the Indian stock exchanges, announcing clinical trial data presentation at ASCO. It contains no financial statements or management discussion of quarterly results, nor is it an investor presentation deck. It is a general regulatory announcement to satisfy listing obligations, fitting the “Regulatory Filings (RNS)” fallback category for miscellaneous compliance disclosures.
2026-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.